ArticleBrazilian journal of cardiovascular surgery2026
Optimization of the in vitro Model of Cardiac Fibrosis.
Article in Brazilian journal of cardiovascular surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDespite the prevalence of cardiac fibrosis, there are currently no effective treatments to reverse it. A major obstacle is the lack of reliable in vitro models. An increase in angiotensin II and collagen occurs in cardiac fibrosis. Therefore, we hypothesized that the combination of angiotensin II with ascorbic acid and dextran sulfate could induce fibrosis in neonatal rat cardiac fibroblasts (nrCFs) and be used as an in vitro model of cardiac fibrosis.
methodsnrCFs were treated with angiotensin II, ascorbic acid, and dextran sulfate. Key features of cardiac fibrosis were evaluated using Alizarin Red, Picrosirius Red, Masson's trichrome staining, quantitative reverse transcription polymerase chain reaction, and immunocytochemistry and scratch assay.
resultsAlthough dextran sulfate increased the expression of alpha-smooth muscle actin (α-SMA), it did not increase collagen deposition and cell migration. Therefore, it seems that the combination of 500 nM angiotensin II with 100 μM ascorbic acid would be effective in induction of cardiac fibrosis in vitro, which increased (1) the expression of collagen, α-SMA, and vimentin at protein level, (2) the expression of collagen type I alpha 1 chain, collagen type III alpha 1 chain, matrix metalloproteinase 2, and transforming growth factor-beta 1 at ribonucleic acid level, and (3) cell proliferation and migration.
conclusionIn this study, 72 hour-treatment of nrCFs with 500 nM angiotensin II and 100 μM ascorbic acid was effective in the creation of an in vitro model of cardiac fibrosis. It is hoped that this model will be useful for screening antifibrotic treatments.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.